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EDITORIALS 
Is Hypomagnesemia or Magnesium Deficiency Arrhythmogenic?* 
BORYS SURAWICZ, MD, FACC 
Indiunapolis, Indiana 
Hypomagnesemia. The increased availability of serum 
magnesium concentration determinations has established 
hypomagnesemia as a common electrolyte disturbance in 
patients with nutritional deficiencies, starvation, alcoholism, 
gastrointestinal disorders, certain types of renal disease and 
a variety of other clinical conditions (1). In patients with 
heart disease, the occurrence of hypomagnesemia is facili- 
tated by treatment with diuretics (2). An increased incidence 
of magnesium deficiency, independent of treatment with 
diuretics, has been reported in patients with ischemic heart 
disease (3), myocardial infarction (4) and mitral valve pro- 
lapse (5). Clinical manifestations of magnesium deficiency 
have been classified into neuromuscular hyperactivity, psy- 
chiatric disturbances, cardiac effects and the effects of 
concurrent hypokalemia or hypocalcemia, or both (6). The 
cardiac effects have largely escaped precise definition, 
but numerous investigators (1,6,7) share the view that 
hypomagnesemia provokes and aggravates cardiac arrhyth- 
mias. 
As implied in the title of this editorial, I consider the 
question of arrhythmia facilitation by hypomagnesemia or 
magnesium deficiency as unsettled because 1) I am not 
aware of any significant electrophysiologic alterations asso- 
ciated with hypomagnesemia that may predispose to ar- 
rhythmias; 2) I am not aware of any animal models in which 
magnesium deficiency is associated with increased incidence 
of arrhythmias; and 3) the meager clinical evidence of the 
association between hypomagnesemia and arrhythmias is 
frequently based on the suppression of arrhythmias by 
administration of magnesium salts. However, the latter 
effect is nonspecific and does not prove that the arrhythmia 
suppressed by magnesium results from the deficiency of this 
cation. 
*Editorials published in Journal of the American College of Cardiology 
reflect the views of the authors and do not necessarily represent the views of 
JACC or the American College of Cardiology. 
From the Krannert Institute of Cardiology, Department of Medicine, 
Indiana University School of Medicine, and the Roudebush Veterans Admin- 
istration Medical Center. Indianapolis, Indiana. This study was supported in 
part by the Herman C. Krannert Fund, Indianapolis: by grants HL-06308 and 
HL-07182 from the National Heart, Lung, and Blood Institute. National 
Institutes of Health, Bethesda, Maryland and the American Heart Associa- 
tion, Indiana Affiliate. Inc., Indianapolis. 
Address for reori&: Borys Surawicz, MD, Krannert Institute of Cardi- 
ology, 1001 West 10th Street, Indianapolis, Indiana 46202. 
The purpose of the ensuing discussion is to list the effects 
of magnesium deficiency and examine critically the validity 
of the hypothesis linking hypomagnesemia to cardiac ar- 
rhythmias. 
Cardiovascular Effects of Magnesium 
Deficiency and Hypomagnesemia 
Magnesium in the myocardial cell. Magnesium is essential 
to normal growth and development. The magnesium com- 
plex with adenosine triphosphate (Mg ATP) is the substrate 
for the enzymatic reaction that underlies the sliding filament 
mechanism of contraction and relaxation (8). Magnesium 
participates in the most vital oxidative, synthetic and trans- 
port processes of the myocardial cell, including the magne- 
sium-dependent uptake and release by and from the sarco- 
plasmic reticulum (8). The calculated intracellular 
concentration of magnesium is 17.3 t 0.2 mrnikg cell H,O 
and that of cytoplasm is assumed to be 51 mm. The 
calculated equilibrium potential is -23 mV. Magnesium ion 
is transported in and out of the cells at a much slower rate 
than the rates of potassium, sodium and chloride. The very 
slow rate of magnesium exchange is independent of the 
frequency of contractions and the external work done by the 
heart (8). Conditions under which the cell membrane may 
become selectively permeable to magnesium have not been 
described, but the question has not been investigated ex- 
haustively (8). 
Effect of magnesium deficiency on ventricular action poten- 
tial. Hoffman and Suckling (9) found that, in the presence of 
normal calcium concentration, a deficiency of magnesium 
had little effect on the action potential of the dog papillary 
muscle. However, when calcium concentration was lowered 
to l/IO of normal, complete omission of magnesium in the 
superfusing solution prolonged the plateau already increased 
in duration by low calcium from a normal value of 100 to 150 
ms to 1,000 ms, or more. In studies of dogs depleted of 
magnesium by means of dialysis reduction of extracellular 
magnesium concentration to less than half of normal con- 
centration failed to produce any electrocardiographic (ECG) 
changes (10). 
In our studies of isolated rabbit hearts (ll), perfusions 
without magnesium lasting up to 22 min produced no 
changes in left intraventricular pressure, shape and duration 
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of ventricular action potential, heart rate, PR interval, or 
shape and duration of the atria1 and ventricular complex in 
the electrocardiogram. When magnesium was omitted from a 
calcium-free solution, the duration of ST segment, QT 
interval and ventricular monophasic action potential in- 
creased. Similar, though less pronounced, changes were 
observed during perfusion with 1116 of normal calcium and 
l/4 to l/l6 of normal magnesium concentration. These ex- 
periments showed that, in the presence of an extremely low 
extracellular calcium concentration, magnesium exerts an 
effect on the current or currents modulating the plateau 
duration of the ventricular action potential. The current in 
question is probably not the slow inward calcium current 
because the calcium channel is not measurably permeable to 
magnesium (12). 
The role of magnesium in modijjkg the duration of the 
ventricular monophasic action potential and the QT interval 
was well illustrated during rapid changes from calcium- 
and magnesium-deficient solutions to calcium-deficient solu- 
tions with high magnesium concentration, with subsequent 
return to calcium- and magnesium-deficient solutions (11). 
During such experiments, rapid successive lengthening and 
shortening of the monophasic action potential and the QT 
interval were produced several times in succession. How- 
ever, the depression of contractility caused by calcium 
deficiency was not altered by changes in magnesium concen- 
tration (11). 
The results of our studies in the isolated perfused rabbit 
hearts suggested that hypomagnesemia may augment 
the QT lengthening induced by hypocalcemia. However, 
clinical studies produced no supporting evidence for 
such a phenomenon (13), probably because the effect of 
magnesium deficiency that modulates the effect of cal- 
cium deficiency on the plateau of the action potential in 
vitro does not become manifest in vivo until the concentra- 
tions of these two ions fall to levels which are not compatible 
with life. 
Hypomagnesemia and the QT interval. As expected from 
the studies in isolated hearts, hypomagnesemia does not 
produce a specific ECG pattern in animals and humans. In 
dogs with prolonged hypomagnesemia and magnesium 
deficiency, transient “changes in the RST segment” were 
noted (14), but there was no definite correlation between the 
ECG and the concentration of serum magnesium. An author- 
itative review (1) refers to QT prolongation by hypo- 
magnesemia, but the sources of the supporting evidence are 
difficult to trace. Personal experience suggests that hypo- 
magnesemia has no detectable effect on the QT interval in 
humans. In fact, in children with tetany, lack of QT prolon- 
gation would favor deficiency of magnesium rather than of 
calcium. 
Systemic Effects of Magnesium Deficiency 
Role of hypocalcemia and depletion of potassium. Ab- 
sence of magnesium in the diet leads to death in animals 
within several months. The symptoms include lack of 
growth, loss of hair, skin lesions, tetany, degenerative 
changes in small vessels, focal myocardial necrosis and 
bradycardia (14-16). The structural abnormalities probably 
reflect the failure of magnesium-dependent oxidative 
phosphorylation (17). Prolonged hypomagnesemia may 
be associated with hypocalcemia but has no effect on 
the levels of serum sodium, chloride, potassium or 
cholesterol (14). However, magnesium deficiency causes 
depletion of muscle potassium (16). This depletion per- 
sists in spite of large intake of potassium, thereby suggest- 
ing that magnesium deficiency may have an influence 
on the ability of cells to maintain an appropriate potassium 
gradient. This particular finding, believed to be present 
in magnesium-depleted patients, is the basis of the 
hypothesis that intracellular potassium depletion predis- 
poses to cardiac arrhythmias that would defy correction in 
the absence of magnesium (18). However, none of the 
studies in animals with chronic magnesium depletion re- 
ported occurrence of cardiac arrhythmias or sudden death 
from arrhythmias (14-16,19). Admittedly, in none of these 
studies were the animals monitored for the purpose of 
arrhythmia detection. 
Effect on digitalis tolerance. Experimental studies in ani- 
mals deprived of magnesium have shown decreased digitalis 
tolerance in magnesium-deficient monkeys (15) and pro- 
longed duration of digitalis toxicity in magnesium-deficient 
puppies (20). However, the clinical application of these 
results is uncertain. It has been shown that patients with 
hypomagnesemia required more rather than less digitalis to 
control ventricular rate in the presence of atria1 fibrillation 
(21). 
Cardiac Arrhythmias in Patients 
With Hypomagnesemia 
The evidence that hypomagnesemia is responsible for 
cardiac arrhythmias is limited to case reports (22-27). In 
some of these, other associated causes could be suspected 
because of either QT prolongation (22,27) or presence of 
hypokalemia on admission (23-25). 
Role in treatment of arrhythmias. Most of the indirect 
evidence linking hypomagnesemia with cardiac arrhythmias 
stems from the effectiveness of magnesium salts in treatment 
of cardiac arrhythmias. Magnesium sulfate solution admin- 
istered intravenously has been used empirically for several 
decades (28,29) to suppress a variety of supraventricular and 
ventricular arrhythmias in the absence and in the presence of 
digitalis therapy (30). The precise mechanism of antiarrhyth- 
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mic action of acute magnesium administration has not been 
elucidated. Magnesium blocks the calcium channel (311, 
shifts the steady state inactivation curve of the fast 
sodium channel in the hyperpolarizing direction (32), modi- 
fies the effect of hyperkalemia (33) and exerts modulating 
effects on several potassium currents (34). In humans. 
infusion of magnesium salts lengthens sinus node recovery 
time, atrioventricular conduction time and QRS duration 
during ventricular pacing (35). A number of these actions 
can influence cardiac arrhythmias and conduction distur- 
bances. 
Conclusions. The question of whether hypomagnesemia 
and magnesium deficiency result in cardiac arrhythmias 
remains unanswered. The absence of ECG and electrophys- 
iologic changes induced by hypomagnesemia deprives us of 
clues to the possible mechanism of arrhythmia induction by 
hypomagnesemia. There are no animal models of arrhyth- 
mias resulting from acute or chronic magnesium deficiency 
(36). There is no doubt that magnesium is useful in the 
treatment of cardiac arrhythmias. However. the favorable 
effect of arrhythmia treatment in patients with hypo- 
magnesemia is difficult to interpret because the antiarrhyth- 
mic properties of magnesium are nonspecific. The lack of 
answers to the question whether hypomagnesemia causes 
arrhythmias makes it difficult to assess the clinical impor- 
tance of magnesium deficiency and to define the therapeutic 
goals of magnesium administration. In most cases. the 
correction of hypomagnesemia and magnesium deficiency 
is probably desirable, but an overzealous treatment may not 
be innocuous, particularly in patients with impaired renal 
function. In addition, an increase of magnesium concentra- 
tion in the operating room may create undesirable cardiac 
effects (37). The rational use of magnesium salts in cardio- 
vascular therapy will require better understanding of the role 
of magnesium deficiency in the genesis of cardiac arrhyth- 
mias. 
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